主要文件

查看所有文档

1292303

USP

格列美脲

Name: 格列美脲
Brand: USP

United States Pharmacopeia (USP) Reference Standard

别名:

Glimepiride

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₄H₃₄N₄O₅S

化学文摘社编号:

93479-97-1

分子量:

490.62

NACRES:

NA.24

PubChem Substance ID:

329749940

UNSPSC Code:

41116107

MDL number:

MFCD00878417

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

glimepiride

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

格列美脲目前用于治疗 2 型糖尿病。

Glimepiride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:

Glimepiride Tablets
Pioglitazone and Glimepiride Tablets

Biochem/physiol Actions

心脏 K_ATP 通道的强力阻断剂。

格列美脲是一种有效的心肌梗死 K_ATP 通道阻断剂，被吡那地尔激活，IC₅₀ 值为 6.8 nM。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 格列美脲

pictograms

GHS08

signalword

Warning

hcodes

H361

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

J Rosenstock et al.

Diabetes care, 19(11), 1194-1199 (1996-11-01)

To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM. Of the previously treated NIDDM patients, 416 entered this multicenter

The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe.

T F Veneman et al.

The Netherlands journal of medicine, 52(5), 179-186 (1998-07-04)

Disturbances in insulin secretion and insulin action are both involved in the pathophysiology of type 2 (or non-insulin-dependent) diabetes mellitus. The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and

Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.

Massimo Massi-Benedetti

Clinical therapeutics, 25(3), 799-816 (2003-07-11)

Sulfonylureas (SUs) have been used for many years as first-line therapy for patients with type 2 diabetes mellitus whose blood glucose levels have not been effectively controlled by diet and exercise alone. Glimepiride is a once-daily SU that was introduced

查看所有相关文献

全球贸易项目编号

货号	GTIN
1292303-200MG	04061838726100